First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
Telix announces that a first patient has been dosed in the ‘PERTINENCE’ Phase I study of TLX250-CDx in patients with non-muscle-invasive bladder...
Read moreLatest News
Category: Clinical
NOBLE Study Brings Advanced Prostate Imaging to Rural Australia – First Patient Dosed
Telix is pleased to announce that the first Australian patient has been dosed in the international NOBLE Registry, a global study that aims to improve access for men to state-of-the-art...
Read more
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
Telix is pleased to announce that a first patient has been dosed in a Phase II study of TLX250-CDx (89Zr-DFO-girentuximab) in patients with triple-negative breast cancer (TNBC) at the Institut...
Read more
Second Industry Body Updates Guidance for Use of PSMA PET Imaging
Telix welcomes the Society of Nuclear Medicine and Molecular Imaging (SNMMI) updated Appropriate Use Criteria (AUC) for prostate specific membrane antigen (PSMA) positron emission tomography (PET)...
Read more
NCCN Guidelines Updated to Include PSMA-PET Imaging
Telix welcomes the updated NCCN Guidelines® for prostate cancer, which includes PSMA PET imaging modalities, including Ga-68...
Read more
FDA Approves Phase II Kidney Cancer Therapy Study
Telix announces the FDA has accepted the IND Application to undertake a clinical study of Telix’s investigational kidney cancer therapy,...
Read more
Japanese Prostate Cancer Imaging Study Completes Enrolment
Telix has completed a Phase I clinical trial of TLX591-CDx for prostate cancer imaging in Japan in collaboration with Kanazawa...
Read more
Telix and Lightpoint Medical to Collaborate on Radioguided Surgery
Telix announces collaboration with Lightpoint Medical to explore molecularly targeted radiation and Lightpoint SENSEI® in radioguided surgery...
Read more
Telix and Merck to Commence Pan-Cancer Clinical Combination Studies
Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt,...
Read more
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
Telix announces two new studies to evaluate the potential utility of TLX591-CDx and TLX250-CDx in breast...
Read more